Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Hisse Senetlerindeki Sıralama #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Hisse Fiyatı
$150.78
Son senkronizasyon: 2026-09-18
Piyasa Değeri
$187.20B
Değişim (1 gün)
-0.08%
Değişim (1 yıl)
32.15%
Ülke
US
Ticaret Gilead Sciences, Inc. (GILD)

Kategori

Gilead Sciences, Inc. (GILD) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-1.96B
Gilead Sciences, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-1.96B'dir. 2024 yılında şirket $690.00M kazanç elde etti, bu 2023 yılındaki $6.86B kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Gilead Sciences, Inc. için kazanç geçmişi 2000 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $-1.96B -119.96%
2025 $9.80B 1,319.71%
2024 $690.00M -89.94%
2023 $6.86B 17.97%
2022 $5.81B -29.77%
2021 $8.28B 395.99%
2020 $1.67B -67.66%
2019 $5.16B -33.84%
2018 $7.80B -42.35%
2017 $13.53B -20.87%
2016 $17.10B -21.06%
2015 $21.66B 45.79%
2014 $14.86B 253.04%
2013 $4.21B 16.50%
2012 $3.61B -1.07%
2011 $3.65B -6.71%
2010 $3.91B 11.75%
2009 $3.50B 31.03%
2008 $2.67B 17.72%
2007 $2.27B -455.74%
2006 $-638.21M -154.93%
2005 $1.16B 76.99%
2004 $656.42M -491.82%
2003 $-167.53M -328.26%
2002 $73.40M 27.76%
2001 $57.45M -237.08%
2000 $-41.91M 0.00%
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$33.59B -1,818.38%
US
$25.20B -1,388.80%
US
$8.70B -544.96%
US
$21.39B -1,194.03%
CH
$5.95B -404.25%
US